100% agree, its great to have you or board. You always bring great content. This tech aims to provide the reassurance and peace of mind of a medical-grade fetal wellness test without the cost or discomfort associated with repeated visits to the OB/GYN or hospital. According to the company, about 50% of expecting mothers in the United States don't have access to an obstetrician, where the cost of pregnancy and newborn care is estimated at about US$30,000.
HeraMED has a distribution agreement with Teva Pharmaceutical Industries (NYSE:TEVA | TASE:TEVA) whose subsidiary Abic is the exclusive distributor of the product in Israel. HeraMED’s partnership with TEVA allows the company to earn US$2+ million over the first three years, delivering product validation, market scope and significant early revenue generation.
